Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.


NDAQ:INM - Post by User

Bullboard Posts
Post by juspam1on Jan 30, 2019 8:46am
211 Views
Post# 29294863

Letter to share holders

Letter to share holdersHeres the bottom line InMed has never been in a better position scientifically, financially, and with our outstanding leadership team than we are today. I would like to take this opportunity to express my gratitude to our incredibly dedicated and diligent in-house team at InMed, as well as our industry partners, for exceptional work on multiple fronts. Without their skills and daily commitment to execution on InMeds programs, we would not be able to share these many achievements of 2018 with you here. I would also like to express my gratitude to you, our valued shareholder, for your continued support in achieving all that we did in 2018, and I look forward to sharing our next round of successes on the scientific and business goals we have set for 2019. We are delighted to have you as a partner as we continue to establish InMed as a global leader in cannabinoid-based therapeutics. On behalf of the entire InMed team, thank you for your continued support. Sincerely, Eric A. Adams President and Chief Executive Officer InMed Pharmaceuticals Inc.
Bullboard Posts